Taste disorders and alopecia in myasthenia gravis

BMC Neurology

Table 1 Clinical features between MG patients with and without taste disorders

	Taste disorders group (n = 104, 6.1%)	Non-taste disorders group (n = 1588, 93.9%)	P value
Female ratio	74.0% (77/104)	59.4% (942/1585)	0.0036
Age at MG onset, y	47.9 ± 14.6	48.1 ± 18.7	0.5972
Disease duration of MG, y	10.2 ± 8.3	12.2 ± 11.3	0.1825
Worst quantitative MG score	16.5 ± 8.0	12.5 ± 6.7	< 0.0001
History of bulbar palsy	64.4% (67/104)	50.0% (786/1569)	0.0060
History of crisis	16.3% (17/104)	7.8% (123/1567)	0.0053
MM or better status, current status	49.0% (51/104)	58.1% (922/1588)	0.0818
Refractory MG	33.7% (35/104)	20.3% (310/1530)	0.0026
MG subtype			< 0.0001
Ocular MG	8.7% (9/104)	22.4% (354/1578)	0.0005
EOMG	20.2% (21/104)	21.3% (336/1578)	0.9015
LOMG	15.4% (16/104)	20.8% (328/1578)	0.2103
TAMG	40.4% (42/104)	21.6% (341/1578)	< 0.0001
MuSKMG	1.0% (1/104)	3.0% (48/1578)	0.3628
SNMG	14.4% (15/104)	10.8% (171/1578)	0.1655
Taste disorders
Onset after MG onset	69.7% (69/99)	-	-
Response to MG treatments	60.4% (58/96)	-	-
Onset after thymectomy	54.7% (35/64)	-	-

Values are presented as the mean ± standard deviation unless otherwise indicated
MG, myasthenia gravis; EOMG, early-onset MG; LOMG, late-onset MG; TAMG, thymoma-associated MG; MuSKMG, MuSK antibody-positive MG; SNMG, seronegative MG; MM, minimal manifestations

ISSN: 1471-2377